39 results about "Atony" patented technology

The invention features polypeptides that include an extracellular ActRIIa variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIa variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, e.g., Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, sarcopenia; or cancer cachexia; or metabolic diseases, e.g., obesity, Type-1 diabetes, or Type-2 diabetes.

The invention features polypeptides that include an extracellular ActRIIB variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIB variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, bone damage, low red blood cell levels (e.g., anemia or blood loss), fibrosis, and / or pulmonary hypertension.

The invention features polypeptides that include an extracellular ActRIIa variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIa variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, e.g., Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, sarcopenia; or cancer cachexia; or metabolic diseases, e.g., obesity, Type-1 diabetes, or Type-2 diabetes.

The invention discloses a method and a system for identifying muscular weakness of a critical patient, and relates to the field of muscular weakness identification. Subjective clinical muscular strength grading of the patient and instrument detection data are integrated, a muscular weakness grade mapping model of multiple parts is established, and the diagnosis accuracy is greatly improved; through a host / guest part mapping model, namely in combination with subjective feeling and objective detection data of a patient, the medullary muscular weakness symptom prone to missed diagnosis in traditional examination can be identified; on the basis of a muscle weakness index data prediction mechanism, a muscle weakness crisis risk can be warned in advance; through a treatment-evaluation-adjustment closed-loop system, dynamic optimization of a medicine scheme is realized, the crisis occurrence rate can be greatly reduced, the dosage of an immunosuppressive agent is reduced, meanwhile, the treatment effect is maintained, and the system is suitable for patient groups managed for a long time; by establishing a mapping system of a part type set and an index grade set, quantitative unified evaluation of different types such as eye muscle type / whole body type and the like is realized, and subjective judgment errors are reduced.

The present invention provides compositions and methods of their use in treating dystroglycanopathy, muscular dystrophy and other disorders. In particular, a method of treating a disorder associated with a mutation or loss of function in a fukutin related protein (FKRP) gene and / or a disorder associated with a defect in glycosylation of α-DG in a subject is provided, comprising administering to the subject an effective amount of a ribitol and a selective estrogen receptor modulator (SERM).

The present invention relates to activin receptor IIA type variants and methods of use thereof. The present invention features a polypeptide comprising an extracellular ActRIIa variant. In some embodiments, the polypeptides of the present invention comprise an extracellular ActRIIa variant fused to an Fc domain monomer or part. The invention also features the treatment of diseases and conditions involving muscle weakness and atrophy using said polypeptides, such as Duchenne muscular dystrophy, facial shoulder brachial muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, sarcopenia; or cancer cachexia; the present invention relates to pharmaceutical compositions and methods for treating a metabolic disease, such as obesity, type 1 diabetes mellitus or type 2 diabetes mellitus.

The present disclosure relates treating skeletal muscle weakness associated with heart failure by administering a compound that binds to leaky ryanodine receptors (RyRs). Compounds of the present disclosure can bind to and repair the leak in both RyR1 and RyR2 to improve skeletal muscle and cardiac function, respectively.

The present invention relates to a method for obtaining a functionally enhanced mitochondria and a use thereof, and specifically, to: a mitochondria isolated from cells overexpressing glutathione synthase; and a use thereof for preventing, alleviating, or treating muscle weakness-related diseases.

The invention features polypeptides that include an extracellular ActRII chimera. In some embodiments, a polypeptide of the invention includes an extracellular ActRII chimera fused to an Fc domain or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness or atrophy of muscles, bone damage, low red blood cell levels (e.g., anemia or blood loss), low platelet levels (e.g., thrombocytopenia), low neutrophil levels (e.g., neutropenia), fibrosis, metabolic disorders, pulmonary hypertension, and / or diseases and conditions that can be treated with erythropoietin or an erythropoiesis-stimulating agent.

The apelin receptor modulator can improve the physical performance of a human patient, slow the progression of age-related weakness, and can reduce age-related muscle weakness. The present disclosure provides methods of treating muscle disorders using specific classes of apelin receptor modulators (e.g., agonists). The muscle condition may be an age-related muscle condition. Also provided is a method of maintaining and / or increasing muscle mass, muscle function, and / or muscle strength in an elderly subject by administering an apelin receptor modulator. In some embodiments, an apelin receptor modulator (e.g., an agonist) is BGE-105 or a pharmaceutically acceptable salt thereof.

The present invention relates to a pharmaceutical composition for preventing or treating diseases related to muscle weakness, which comprises alverine, 4-hydroxyalverine, a derivative thereof or a pharmaceutically acceptable salt thereof. When myoblasts are treated with alverine, 4-hydroxyalverine, a derivative thereof or a pharmaceutically acceptable salt thereof of the present invention, differentiation into myotubes is promoted. Therefore, alverine, 4-hydroxyalverine, a derivative thereof or a pharmaceutically acceptable salt thereof according to the present invention can be effectively used to promote differentiation of myoblasts and prevent or treat diseases related to muscle weakness.

The invention features polypeptides that include an extracellular ActRII chimera. In some embodiments, a polypeptide of the invention includes an extracellular ActRII chimera fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, bone damage, low red blood cell levels (e.g., anemia or blood loss), low platelet levels (e.g., thrombocytopenia), low neutrophil levels (e.g., neutropenia), fibrosis, metabolic disorders, and / or pulmonary hypertension.

There are provided polypeptides that include an Activin receptor type IIB (ActRIIB) ectodomain (ECD) variant. In some embodiments, a polypeptide of the disclosure includes an ActRIIB-ECD variant fused to an Fc domain moiety. The disclosure also provides pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions associated with TGFβ superfamily ligand signaling, such as pulmonary hypertension, fibrosis, muscle weakness and atrophy, metabolic disorders and / or cardiometabolic disease, bone damage, and / or low red blood cell levels (such as anemia).

The present invention relates to activin receptor IIA type variants and methods of use thereof. The present invention features a polypeptide comprising an extracellular ActRIIa variant. In some embodiments, the polypeptides of the present invention comprise an extracellular ActRIIa variant fused to an Fc domain monomer or part. The invention also features the treatment of diseases and conditions involving muscle weakness and atrophy using said polypeptides, such as Duchenne muscular dystrophy, facial shoulder brachial muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, sarcopenia; or cancer cachexia; the present invention relates to pharmaceutical compositions and methods for treating a metabolic disease, such as obesity, type 1 diabetes mellitus or type 2 diabetes mellitus.

According to the WHO, the population aged 60 and over will have doubled by 2050. Unfortunately, aging comes along with an explosion of aging-associated disorders, such as metabolic and cardiovascular diseases, bone and muscle weakening, cognitive dysfunction, that all contribute to the loss of functional capacities, leading to frailty and dependence. Now, the inventors reveal a premature aging phenotype, associating metabolic defects and muscle weakness, in a mouse model of Noonan Syndrome. Both clinical traits are linked to myeloid cells dysfunction and increased senescence, highlighting the role of SHP2 hyperactivation in the onset of aging-associated diseases. Thus the present invention relates to the use of SHP2 inhibitors for inhibiting senescence.

Disclosed are methods of improving weight loss, reducing body weight, reducing body fat mass, reducing muscle loss, reducing muscle atrophy, reducing muscle weakness, increasing muscle mass, and / or increasing muscle strength in a patient being treated with a GLP-1 receptor agonist, by administering to the patient a compound of formula (I) or a pharmaceutically acceptable salt thereof. Combinations of a GLP-1 receptor agonist and a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in improving weight loss, reducing body weight, reducing body fat mass, reducing muscle loss, reducing muscle atrophy, reducing muscle weakness, increasing muscle mass, and / or increasing muscle strength in a patient are also provided.

The invention discloses a traditional Chinese medicine composition for treating Bell paralysis sequelae. The traditional Chinese medicine composition is prepared from the following raw material medicines: astragalus membranaceus, angelica sinensis, radix rehmanniae preparata, ligusticum wallichii, parched white peony root, kudzu vine root, cortex albiziae, pawpaw, semen coicis, lycopodium clavatum, caulis spatholobi and angelica dahurica. The invention further discloses a traditional Chinese medicine compound preparation for treating the Bell paralysis sequelae and application of the traditional Chinese medicine composition or the traditional Chinese medicine compound preparation to preparation of medicine for treating the Bell paralysis sequelae. The traditional Chinese medicine composition has a remarkable curative effect on Bell facial paralysis sequelae such as mouth-eye linkage, facial spasm and facial muscle tension and weakness, can remarkably relieve facial tension, relieve mouth-eye linkage, relieve facial spasm and improve the living quality and mental state of a patient, is remarkable in treatment effect, can adjust and add or reduce the formula according to specific diseases, and is free of toxic and side effects. The method has great popularization and application values.

Disclosed are methods of improving weight loss, reducing body weight, reducing body fat mass, reducing muscle loss, increasing muscle mass, and / or increasing muscle strength in a subject being treated with a GLP-1 receptor agonist, by administering to the subject a compound of formula (I) or a pharmaceutically acceptable salt thereof. Combinations of a GLP-1 receptor agonist and a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in improving weight loss, reducing body weight, reducing body fat mass, reducing muscle loss, reducing muscle atrophy, reducing muscle weakness, increasing muscle mass, and / or increasing muscle strength in a subject are also provided.

Disclosed herein are products, methods, and uses for treating, ameliorating, delaying the progression of, and / or preventing a disease or disorder associated with expression of an aberrant lamin A (LMNA) gene or progerin gene. Such disease or disorder includes, but is not limited to, a laminopathy, progeroid syndrome, progeria, or aging disorder resulting from the aberrant expression of LMNA or progerin. In some instances, the progeria is Hutchinson-Gilford progeria syndrome (HGPS). In some instances, the disease or disorder associated with the expression of progerin is premature aging or natural aging including, but not limited to, atherosclerosis, alopecia, osteoporosis, cardiovascular disease, skin abnormalities, fat storage, stroke, myocardial infarction, stroke, heart failure, muscle wasting, muscle weakness, myotonia, skeletal muscle problems, abnormalities of the retina, hip weakness, abdominal muscle weakness, joint and spinal abnormalities, lower leg weakness, shoulder weakness, hearing loss, and / or tissue inflammation. More particularly, disclosed herein are RNA interference-based products, methods, and uses for inhibiting or downregulating the expression of progerin. Even more particularly, the disclosure provides guide RNA and a CRISPR endonuclease for inhibiting or downregulating the expression of progerin and methods of using said guide RNA and a CRISPR endonuclease to correct a mutation in the LMNA gene and inhibit or downregulate progerin expression in cells and / or in cells of a subject having a condition resulting from the expression of progerin including, but not limited to, HGPS or progeria, an HGPS-like condition affecting LMNA mutations that affect exon 11 splicing, or a condition resulting from the expression of progerin.

The invention relates to a pharmaceutically acceptable acid addition salt of: (i) S-pindolol; and (ii) an organic acid, wherein the organic acid has: a pKa1 of greater than or equal to 2.5; and a chemical formula of CxHy(CO2H)z, where x is from 1 to 10, y is from 2 to 20 and z is 1 or 2. The pharmaceutically acceptable acid addition salt is useful in treating conditions such as cachexia, sarcopenia, a neuromuscular disorder and muscle weakness.

A combination of creatine and at least one of oleuropein or metabolite thereof for use by oral administration to an individual in an amount effective to achieve at least one result that is (i) improved mitochondrial calcium uptake in muscle cells. (ii) improved utilization of calcium in muscle cells, (iii) increased mitochondrial energy in muscle cells, (iv) improvement in at least one of muscle functionality, muscle performance, lean muscle mass or muscle strength, (v) decreased muscle fatigue, (vi) increased mobility, and / or (vii) treatment of a muscle disorder linked to calcium depletion or deficiency. The individual can be at least one of an aging subject; an elderly subject; a subject with muscle fatigue or muscle weakness; a subject with impaired mobility; a frail subject; a pre-frail subject; a sarcopenic subject; a subject recovering from pre-frailty, frailty, sarcopenia or impaired mobility; a subject undergoing physical rehabilitation; a sportsman; or a pet.

The present invention relates to a use of a novel compound, for preventing, improving or treating amyotrophic lateral sclerosis (ALS). The present inventors have found that SOD1 aggregation is one of the important causes of ALS, and have proposed the possibility that WT-SOD1 aggregation, caused by suppressing the regulation of intracellular stress or TDP-43, may be a cause of sALS. In addition, the present inventors have discovered the novel compound PRG-A-01 (SLC-B036) as a SOD1 aggregation and misfolding inhibitor. The compound exhibited a protective effect against muscle weakness and movement disorder in an ALS mouse model. According to the result of a histological analysis, intraspinal nerves were maintained by means of a treatment using PRG-A-01 (SLC-B036). In addition, the present inventors have obtained a candidate compound (PRG-A-04) which can be a more optimized drug. Consequently, the compound of the present invention may be usefully employed in developing a therapeutic agent for ALS.

To provide a method for treating an individual for one or more kinds of medical conditions or physical conditions.SOLUTION: The present invention relates to a composition and a method related to utilization of glycine and N-acetylcysteine for various medical conditions related to reduction in glycine, N-acetylcysteine, and / or glutathione level. The medical conditions are (a) muscular weakness, (b) adverse effect of zero gravity, (c) organ failure, (d) cardiac function or heart failure, (e) cancer prevention, (f) metabolism programming of fetus for preventing obesity and / or onset after diabetes, (g) health of mother's body and fetus in gestational diabetes, and (h) exercise capacity and physical function, for example.SELECTED DRAWING: Figure 1

To provide polypeptides that include an extracellular ActRII chimera.SOLUTION: Provided is a polypeptide of the present invention including an extracellular ActRII chimera fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, bone damage, low red blood cell levels (e.g., anemia or blood loss), low platelet levels (e.g., thrombocytopenia), low neutrophil levels (e.g., neutropenia), fibrosis, metabolic disorders, and / or pulmonary hypertension.SELECTED DRAWING: None

The invention features polypeptides that include an extracellular ActRIIa variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIa variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, e.g., Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, sarcopenia; or cancer cachexia; or metabolic diseases, e.g., obesity, Type-1 diabetes, or Type-2 diabetes.

Disclosed herein are products, methods, and uses for treating, ameliorating, delaying the progression of, and / or preventing a disease or disorder associated with expression of an aberrant lamin A (LMNA) gene or progerin gene. Such disease or disorder includes, but is not limited to, a laminopathy, progeroid syndrome, progeria, or aging disorder resulting from the aberrant expression of LMNA or progerin. In some instances, the progeria is Hutchinson-Gilford progeria syndrome (HGPS). In some instances, the disease or disorder associated with the expression of progerin is premature aging or natural aging including, but not limited to, atherosclerosis, alopecia, osteoporosis, cardiovascular disease, skin abnormalities, fat storage, stroke, myocardial infarction, stroke, heart failure, muscle wasting, muscle weakness, myotonia, skeletal muscle problems, abnormalities of the retina, hip weakness, abdominal muscle weakness, joint and spinal abnormalities, lower leg weakness, shoulder weakness, hearing loss, and / or tissue inflammation. More particularly, disclosed herein are RNA interference-based products, methods, and uses for inhibiting or downregulating the expression of progerin. Even more particularly, the disclosure provides guide RNA and a CRISPR endonuclease for inhibiting or downregulating the expression of progerin and methods of using said guide RNA and a CRISPR endonuclease to correct a mutation in the LMNA gene and inhibit or downregulate progerin expression in cells and / or in cells of a subject having a condition resulting from the expression of progerin including, but not limited to, HGPS or progeria, an HGPS-like condition affecting LMNA mutations that affect exon 11 splicing, or a condition resulting from the expression of progerin.

The disclosure features methods for treating or ameliorating at least one symptom of a subject having or being prone to a muscle weakness disease by administering to the subject a therapeutically effective amount of at least one recombinant polypeptide having alkaline phosphatase activity. The subject is characterized as lacking a loss-of-function mutation in an ALPL gene.

The disclosure features methods for treating or ameliorating at least one symptom of a subject having or being prone to a muscle weakness disease by administering to the subject a therapeutically effective amount of at least one recombinant polypeptide having alkaline phosphatase activity. The subject is characterized as lacking a loss-of-function mutation in an ALPL gene.

The present invention relates to a composition for preventing, improving, or treating diseases associated with muscle weakness, comprising a celery seed extract. The celery seed extract according to the present invention is a natural product and can increase muscle mass and strength with few or no side effects. Therefore, it is expected that the celery seed extract according to the present invention can be useful for preventing, improving, or treating diseases associated with muscle weakness, metabolic diseases, liver diseases, etc., since it can increase muscle mass and strength with few or no side effects by using a natural product and can not only prevent muscle weakness, but also inhibit increases in body weight and body fat, and reduce blood lipid concentrations and liver toxicity indicators (GOT and GPT).

The utility model discloses an exoskeleton support system for lower limb muscle asthenic, aims at solving the problem that the existing support device cannot adjust support force according to the rehabilitation stage demand. The system comprises a square frame, a moving mechanism, a vertical connecting plate, a sliding slot, a sliding block, a motor, a mounting plate and a support mechanism. The support mechanism is composed of a support column and a moving column, is provided with a telescopic rod and a tension spring, and can adjust the support degree. The binding belt and the adjusting belt can be adjusted individually according to the patient condition. The system reduces the dependence on the physiotherapist, improves the rehabilitation resource efficiency, is suitable for rehabilitation training and daily life assistance, has simple structure, low cost and economy.